results

Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2025

September 26, 2025 16:04 ET  | Source: Maris-Tech Ltd. The company continues to advance AI-powered video streaming and edge computing…

10 months ago

Medicenna Announces Results of Annual Meeting of Shareholders

TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage…

10 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

September 25, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) --…

10 months ago

Verano to Report Third Quarter 2025 Financial Results on October 29, 2025

CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a…

10 months ago

Euro NCAP to Launch New 2025 Assisted Driving Results

WhatLatest Euro NCAP AD results published online and via social media.WhenWednesday 24 September - 11:00 a.m. CEST.WhereGo to Euro NCAP's Press Releases or access videos…

10 months ago

Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00…

10 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

September 19, 2025 16:18 ET  | Source: MBX Biosciences, Inc. CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences,…

10 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

10 months ago

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

September 07, 2025 18:25 ET  | Source: Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE)…

11 months ago

Cango Inc. Reports Second Quarter 2025 Unaudited Financial Results

HONG KONG, Sept. 4, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) today announced its unaudited financial results for the second quarter…

11 months ago